The present invention relates to a modified-release composition comprising orlistat and acarbose, comprising individually distinct parts with different release patterns:
a) a first part, G1, comprising from about 5 to about 70% w/w of the total dose of acarbose,
b) a second part, G2A, comprising from about 30 to about 95% w/w of the total dose of acarbose,
c) a third part, G2B, comprising from about 10 to about 90% w/w of the total dose of orlistat, and
d) a fourth part, G3, comprising from about 10 to about 80% w/w of the total dose of orlistat, and the total concentration of acarbose and orlistat, respectively, in the composition is 100% w/w.
The invention relates to a composition of orlistat and acarbose for use in improving quality of life. The combination is administered orally to obtain a synergistic effect. The synergistic effect is obtained after 13 weeks or more such a after 14 weeks or more. after 15 weeks or more. after 16 weeks or more. after 17 weeks or more. after 18 weeks or more. after 19 weeks or more. after 20 weeks or more. after 21 weeks or more. after 22 weeks or more. after 23 weeks or more. after 24 weeks or more. after 25 weeks or more of after 26 weeks or more of treatment. The synergistic effect gives improved weight loss.
The invention relates to a composition of orlistat and acarbose for use in improving quality of life. The combination is administered orally to obtain a synergistic effect. The synergistic effect is obtained after 13 weeks or more such a after 14 weeks or more, after 15 weeks or more, after 16 weeks or more, after 17 weeks or more, after 18 weeks or more, after 19 weeks or more, after 20 weeks or more, after 21 weeks or more, after 22 weeks or more, after 23 weeks or more, after 24 weeks or more, after 25 weeks or more of after 26 weeks or more of treatment. The synergistic effect gives improved weight loss.
The present invention relates to a method for body weight management, the method comprises treating a subject with acarbose and orlistat to reduce fluctuations in body weight so that the body weight of said subject stays within a range of ±6% within a 6-month period such as ±3% within a 3-month period from the body weight resulting after the subject has been treated with a weight- lowering drug substance. The treatment with acarbose and orlistat starts when the treatment with said weight-lowering drug substance terminates or it starts from 1 to 4 weeks before the treatment with said weight-lowering drug substance terminates.
The invention relates to a composition of orlistat and acarbose for use in improving quality of life. The combination is administered orally to obtain a synergistic effect. The synergistic effect is obtained after 13 weeks or more such a after 14 weeks or more, after 15 weeks or more, after 16 weeks or more, after 17 weeks or more, after 18 weeks or more, after 19 weeks or more, after 20 weeks or more, after 21 weeks or more, after 22 weeks or more, after 23 weeks or more, after 24 weeks or more, after 25 weeks or more of after 26 weeks or more of treatment. The synergistic effect gives improved weight loss.
The present invention relates to a modified-release composition comprising orlistat and acarbose, comprising individually distinct parts with different release patterns: a) a first part, G1, comprising from about 5 to about 70% w/w of the total dose of acarbose, b) a second part, G2A, comprising from about 30 to about 95% w/w of the total dose of acarbose, c) a third part, G2B, comprising from about 10 to about 90% w/w of the total dose of orlistat, and d) a fourth part, G3, comprising from about 10 to about 80% w/w of the total dose of orlistat, and the total concentration of acarbose and orlistat, respectively, in the composition is 100% w/w.
The present invention relates to a modified-release composition comprising orlistat and acarbose, comprising individually distinct parts with different release patterns: a) a first part, G1, comprising from about 5 to about 70% w/w of the total dose of acarbose, b) a second part, G2A, comprising from about 30 to about 95% w/w of the total dose of acarbose, c) a third part, G2B, comprising from about 10 to about 90% w/w of the total dose of orlistat, and d) a fourth part, G3, comprising from about 10 to about 80% w/w of the total dose of orlistat, and the total concentration of acarbose and orlistat, respectively, in the composition is 100% w/w.
The present invention relates to a modified-release composition comprising orlistat and acarbose, comprising individually distinct parts with different release patterns: a) a first part, G1, comprising from about 5 to about 70% w/w of the total dose of acarbose, b) a second part, G2A, comprising from about 30 to about 95% w/w of the total dose of acarbose, c) a third part, G2B, comprising from about 10 to about 90% w/w of the total dose of orlistat, and d) a fourth part, G3, comprising from about 10 to about 80% w/w of the total dose of orlistat, and the total concentration of acarbose and orlistat, respectively, in the composition is 100% w/w.
The present invention relates to a modified-release composition comprising orlistat and acarbose, comprising individually distinct parts with different release patterns: a) a first part, G1, comprising from about 5 to about 70% w/w of the total dose of acarbose, b) a second part, G2A, comprising from about 30 to about 95% w/w of the total dose of acarbose, c) a third part, G2B, comprising from about 10 to about 90% w/w of the total dose of orlistat, and d) a fourth part, G3, comprising from about 10 to about 80% w/w of the total dose of orlistat, and the total concentration of acarbose and orlistat, respectively, in the composition is 100% w/w.
patents
